Hologic, Inc. (NASDAQ:HOLX) Position Boosted by OneDigital Investment Advisors LLC

OneDigital Investment Advisors LLC raised its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 5.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,075 shares of the medical equipment provider’s stock after acquiring an additional 360 shares during the period. OneDigital Investment Advisors LLC’s holdings in Hologic were worth $576,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of HOLX. Price T Rowe Associates Inc. MD grew its stake in shares of Hologic by 77.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock worth $490,931,000 after purchasing an additional 2,753,016 shares during the last quarter. Swedbank AB purchased a new stake in Hologic in the 1st quarter worth about $120,827,000. Black Creek Investment Management Inc. increased its stake in Hologic by 60.9% in the 2nd quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock valued at $173,669,000 after buying an additional 885,524 shares during the period. Mackenzie Financial Corp grew its holdings in shares of Hologic by 1,023.3% during the 2nd quarter. Mackenzie Financial Corp now owns 895,699 shares of the medical equipment provider’s stock valued at $66,506,000 after acquiring an additional 815,960 shares in the last quarter. Finally, Marshall Wace LLP acquired a new position in shares of Hologic in the second quarter worth $39,427,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. UBS Group increased their price target on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Royal Bank of Canada raised their price objective on shares of Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a research note on Tuesday, November 5th. Mizuho cut their price objective on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Tuesday, November 5th. Evercore ISI boosted their price target on shares of Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a report on Tuesday, October 1st. Finally, Citigroup downgraded Hologic from a “buy” rating to a “neutral” rating and cut their target price for the stock from $95.00 to $85.00 in a research report on Tuesday, October 1st. Four research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $89.91.

Hologic Stock Down 0.7 %

Shares of NASDAQ HOLX opened at $78.04 on Thursday. Hologic, Inc. has a 52-week low of $67.59 and a 52-week high of $84.67. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. The stock has a market cap of $18.13 billion, a P/E ratio of 23.44, a P/E/G ratio of 2.48 and a beta of 0.98. The firm has a 50 day moving average price of $80.52 and a 200 day moving average price of $78.30.

Hologic (NASDAQ:HOLX) last posted its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.01. The business had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. Hologic’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.89 EPS. Analysts expect that Hologic, Inc. will post 4.27 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.